Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

A. Soares,F. Monteiro,F. Maluf,D. Bastos,D. Jardim,A. Sasse,A. Gonçalves e Silva,A. Fay,D. A. R. Da Rosa,Evanius Wierman,F. Kater,F. Schutz,F. D. de Oliveira,I. P. Morbeck,J. Rinck,K. M. da Trindade,M. Maia,V. C. Souza,Deusdedit Cortez Vieira da Silva Neto,Felipe de Almeida e Paula,F. Korkes,G. Carvalhal,L. Nogueira,Roni de Carvalho Fernandes,R. B. Dos Reis,W. Matheus,W. Busato,W. D. da Costa,Stênio de Cássio Zequi

Published 2020 in Journal of Cancer Research and Clinical Oncology

ABSTRACT

Purpose The outcome of RCC has improved considerably in the last few years, and the treatment options have increased. LACOG-GU and LARCG held a consensus meeting to develop guidelines to support the clinical decisions of physicians and other health professionals involved in the care of RCC patients. Methods Eighty questions addressing relevant advanced RCC treatments were previously formulated by a panel of experts. The voting panel comprised 26 specialists from the LACOG-GU/LARCG. Consensus was determined as 75% agreement. For questions with less than 75% agreement, a new discussion was held, and consensus was determined by the majority of votes after the second voting session. Results The recommendations were based on the highest level of scientific evidence or by the opinion of the RCC experts when no relevant research data were available. Conclusion This manuscript provides guidance for advanced RCC treatment according to the LACOG-GU/LARCG expert recommendations.

PUBLICATION RECORD

Publication year
2020
Venue
Journal of Cancer Research and Clinical Oncology
Publication date
2020-05-14
Fields of study
Medicine
Identifiers
DOI 10.1007/s00432-020-03236-4 PMID 32410064 PMCID 7256074
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)
2023cited by this paper
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
2021cited by this paper
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
2020cited by this paper
First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.
2020cited by this paper
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
2019cited by this paper
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
2019cited by this paper
Managing Clonal Hematopoiesis in Patients With Solid Tumors.
2019cited by this paper
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
2019cited by this paper
First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B
2019cited by this paper
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
2019cited by this paper
CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
2019cited by this paper
The role of metastasectomy in advanced renal cell carcinoma
2019cited by this paper
Hyperprogressive disease in patients with metastatic genitourinary tumors treated with immune checkpoint inhibitors.
2019cited by this paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
2019cited by this paper
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
2019cited by this paper
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
2019cited by this paper
Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).
2019cited by this paper
First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
2019cited by this paper
TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
2019cited by this paper
Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.
2019cited by this paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
2019cited by this paper
Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma
2019cited by this paper
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
2019cited by this paper
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
2018cited by this paper
Personalized Management of Advanced Kidney Cancer.
2018cited by this paper
IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
2018cited by this paper
Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
2018cited by this paper
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma
2018cited by this paper
TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery
2018cited by this paper
Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma
2018cited by this paper
Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors.
2018cited by this paper
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
2018cited by this paper
Association of low PTEN expression by fluorescence immunohistochemistry (F-IHC) and lethal disease in men with surgically-treated prostate cancer (PrCa).
2018cited by this paper
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
2018cited by this paper
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
2017cited by this paper
Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta‐Analysis
2017cited by this paper
Cancer statistics, 2017
2017cited by this paper
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
2017cited by this paper
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
2017cited by this paper
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial
2017cited by this paper
Systemic Therapy for Metastatic Renal-Cell Carcinoma.
2017cited by this paper
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
2016cited by this paper
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
2016cited by this paper
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
2016cited by this paper
Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
2016cited by this paper
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.
2016cited by this paper
Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).
2015cited by this paper
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
2015cited by this paper
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
2015cited by this paper
Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
2015cited by this paper
International variations and trends in renal cell carcinoma incidence and mortality.
2015cited by this paper
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
2015cited by this paper
Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.
2015cited by this paper
PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
2015cited by this paper
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
2015cited by this paper
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
2014cited by this paper
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
2014cited by this paper
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
2014cited by this paper
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
2014cited by this paper
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma
2014cited by this paper
Local treatments for metastases of renal cell carcinoma: a systematic review.
2014cited by this paper
5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib
2014cited by this paper
Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
2014cited by this paper
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
2013cited by this paper
Renal Medullary Carcinoma Response to Chemotherapy: a Referral Center Experience in Brazil
2013cited by this paper
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
2013cited by this paper
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
2013cited by this paper
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
2013cited by this paper
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
2013cited by this paper
Reducing the burden of bone metastases
2013cited by this paper
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
2013cited by this paper
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
2012cited by this paper
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
2011cited by this paper
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
2011cited by this paper
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis
2010cited by this paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
2010cited by this paper
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma
2010cited by this paper
Phase 3 trial of everolimus for metastatic renal cell carcinoma
2010cited by this paper
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
2009cited by this paper
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
2009cited by this paper
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
2009cited by this paper
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
2009cited by this paper
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
2008cited by this paper
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.
2008cited by this paper
Patients’ needs assessment in cancer care: a review of assessment tools
2007cited by this paper
Suffering with advanced cancer.
2007cited by this paper
Sorafenib in advanced clear-cell renal-cell carcinoma.
2007cited by this paper
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
2007cited by this paper
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
2007cited by this paper
Renal medullary carcinoma: the Bronx experience.
2007cited by this paper
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience.
2006cited by this paper
Proven bioequivalence of blood exposure between vinorelbine 80 mg/m2 oral and 30 mg/m2 IV doses in cancer patients
2005cited by this paper
Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group.
2005cited by this paper
Systematic review of the diagnosis and management of malignant extradural spine cord compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group.
2005cited by this paper
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration
2005cited by this paper
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
2005cited by this paper
Morphological classification of renal cancer
2004cited by this paper
Palliative Care: the World Health Organization's global perspective.
2002cited by this paper
Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype.
2002cited by this paper
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
2001cited by this paper